Valuation: Alvotech

Market Cap 1.21B 1.05B 975M 900M 1.7B 116B 1.73B 11.62B 4.56B 56.74B 4.53B 4.43B 195B P/E 2026 *
9.17x
P/E 2027 * 7.83x
Enterprise Value 2.25B 1.97B 1.82B 1.68B 3.17B 217B 3.23B 21.72B 8.52B 106B 8.47B 8.28B 365B EV / Sales 2026 *
3.41x
EV / Sales 2027 * 2.86x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-3.99%
1 week-2.31%
Current month-8.40%
1 month-18.94%
3 months-8.89%
6 months-30.02%
Current year-34.11%
1 week 3.24
Extreme 3.245
3.49
1 month 3.24
Extreme 3.245
4.34
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Sell

Founder

318,000 0.0963%
01/04Free

Chief Executive Officer

117,271 0.0355%
01/04Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%-2.31%-60.33%-60.79% 1.21B
-1.05%+1.39%+3.15%+6.98% 50.61B
+0.83%-2.58%+383.58%+595.99% 39.11B
-0.00%-0.23%+29.74%-6.03% 34.64B
+1.02%-0.49%+21.94%+56.60% 33.79B
-1.31%-1.76%+1.59%+27.01% 26.89B
+0.82%+0.06% - - 16.47B
+1.33%-1.43%+68.09%+121.41% 15.14B
-0.72%+0.12%+14.69%+16.95% 13.85B
+1.25%-0.14%+12.69%-31.58% 12.72B
Average -0.17%-1.70%+52.79%+80.73% 24.44B
Weighted average by Cap. +0.07%-1.15%+80.27%+121.47%

Financials

2026 *2027 *
Net sales 661M 577M 534M 493M 929M 63.47B 946M 6.37B 2.5B 31.08B 2.48B 2.43B 107B 800M 699M 646M 597M 1.12B 76.82B 1.14B 7.7B 3.02B 37.62B 3B 2.94B 130B
Net income 165M 144M 133M 123M 231M 15.81B 236M 1.59B 622M 7.74B 618M 605M 26.66B 134M 117M 109M 100M 189M 12.91B 192M 1.29B 508M 6.32B 505M 494M 21.76B
Net Debt 1.05B 916M 847M 782M 1.47B 101B 1.5B 10.1B 3.96B 49.3B 3.94B 3.85B 170B 1.08B 944M 873M 807M 1.52B 104B 1.55B 10.41B 4.09B 50.83B 4.06B 3.97B 175B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
13/07/26 USD 3.380 +3.05% 727,563
10/07/26 USD 3.280 -1.20% 397,734
09/07/26 USD 3.320 -2.35% 629,021
08/07/26 USD 3.400 -2.58% 385,125
07/07/26 USD 3.490 +0.87% 638,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.380USD
Average target price
14.60USD
Spread / Average Target
+331.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock